OncoCyte hosting KOL webinar on DetermaIO » 08:1906/2206/22/22
Oncocyte Corporation announced that it will host a key opinion leader webinar on the role of DetermalO and the tumor microenvironment in clinical practice on Tuesday, June 28, 2022, at 10:00am Eastern Time. The webinar will feature presentations from KOLs Chiara Cremolini, MD, PhD, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy, and Adam Brufsky, MD, PhD, University of Pittsburgh School of Medicine. Dr. Cremolini will provide an expert data overview on the ASCO 2022 poster session: An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the phase II randomized AtezoTRIBE study. Subsequently, Dr. Brufsky and Dr.Cremolini will take part in an expert fireside chat on assessing the tumor micro-environment to identify potential responders to immunotherapy in Colon and Breast Cancer, and review how this could impact clinical practice and management of patients.
|Over a month ago|
OncoCyte presents DetermaIO data at ASCO supporting immunotherapy expansion » 17:1405/2605/26/22
Oncocyte "announced new data from ongoing clinical research evaluating the utility of DetermaIO, the Company's proprietary test designed to determine the likelihood of benefit of immune checkpoint inhibitors, at the upcoming American Society of Clinical Oncology Annual Meeting, ASCO, taking place June 3-7, 2022 virtually and in-person in Chicago. DetermaIO was launched via an Early Access Program in Q4 of 2021 and is the first and only commercial test to assess multiple components of the tumor immune microenvironment, giving insight into the biology of the tumor that allows for physicians and their patients to make informed decisions about their treatment journey. The three posters to be presented by Oncocyte add to the growing body of evidence showing that the test identifies patients who respond to ICIs - including Keytruda, Opdivo, Tecentriq and Imfinzi - in lung, bladder, kidney, triple-negative breast, and now colon and gastric cancers, suggesting a pan-cancer utility for the test in both primary and metastatic settings."
Stephens downgrades OncoCyte to Equal Weight on limited near-term upside » 11:0005/2405/24/22
As reported before the…
As reported before the open, Stephens analyst Mason Carrico downgraded OncoCyte to Equal Weight from Overweight with a price target of $1.25, down from $2. While he continues to see long-term value in OncoCyte's portfolio, he sees relatively limited near-term upside with timelines having been pushed out in recent quarters, Carrico told investors. Though he expects a strong ramp in TheraSure test volumes, relatively minimal reimbursement and a small commercial team could result in lower than anticipated revenue in FY23 while DetermaIO likely won't begin contributing revenue until 2024, Carrico said.
OncoCyte downgraded to Equal Weight from Overweight at Stephens » 07:5405/2405/24/22
Stephens analyst Mason…
Stephens analyst Mason Carrico downgraded OncoCyte to Equal Weight from Overweight.
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler » 21:1505/1505/15/22
Piper Sandler analyst…
Piper Sandler analyst David Westenberg lowered the firm's price target on OncoCyte to $1.40 from $1.80 and keeps an Overweight rating on the shares post the earnings release. The analyst dropped price targets in the life science tools and genomics space to reflect movements in comp valuations.
OncoCyte reports Q1 EPS (11c), consensus (12c) » 16:1605/1105/11/22
Reports Q1 revenue $1.4M,…
Reports Q1 revenue $1.4M, consensus $2.24M. "We continued to make solid progress in the first quarter, delivering 73% year over year growth in DetermaRx sample volumes and successfully onboarding new physicians and accounts. We also successfully completed an underwritten financing to strengthen our balance sheet and fuel our upcoming product launch efforts," said Ron Andrews, President and Chief Executive Officer of Oncocyte. "Looking ahead, we remain enthusiastic about our upcoming DetermaIO data releases at ASCO in early June and the continued rapid progress we have made to launch our transplant business as we announced last week. We also remain on track to submit three additional oncology tests, DetermaIO, DetermaTx and DetermaCNI, for reimbursement over the next 12-18 months. I appreciate the continued support of our shareholders and look forward to updating you as we execute on our strategic plans."
OncoCyte completes validation of TheraSure Transplant Monitoring test » 08:3905/0505/05/22
Oncocyte announced that…
Oncocyte announced that it has completed development of its proprietary TheraSure Transplant Monitoring test for liver transplant patients. This announcement marks the successful completion of technology transfer and Oncocyte's readiness to deploy TheraSure following the Company's acquisition of Chronix Biomedical. "Today's announcement marks the first product to be launched clinically from our Chronix acquisition completed in April 2021. The tech transfer of the proprietary blood based technology used to develop TheraSure was an important undertaking for our R&D team in Germany and our CLIA lab team in Nashville, and I am extremely proud of the herculean effort put forth to meet the aggressive timeline we set last year to put us in a position to launch the liver indication in the first half of 2022," said Ron Andrews, President and CEO of Oncocyte. "Management believes that the streamlined workflow developed by our two expert PCR development teams paves the way for expedited validation of TheraSure for kidney and heart transplants and prepares the Company for the important work ahead to convert the lab workflow into a kit."
Fly Insider: Sonic Automotive, Moderna among week's notable insider trades » 15:4004/1804/18/22
CMPO, PRTY, SAH, OCX, CERE, ETSY, HUBS, MRNA
Welcome to "Fly Insider,"…
OncoCyte 26.27M share Spot Secondary priced at $1.33 » 06:2504/1404/14/22
OncoCyte announced today…
OncoCyte announced today the pricing of an underwritten public offering of 26,266,417 shares of its common stock, together with warrants to purchase up to an aggregate of 13,133,208.5 shares of its common stock. Each share of common stock is being sold together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325 for total gross proceeds of approximately $35 million, before underwriting discounts and commissions and offering expenses payable by Oncocyte. The warrants have an exercise price of $1.53 per share, are exercisable immediately, and will expire five years following the date of issuance. The offering is expected to close on or about April 19, 2022, subject to the satisfaction or waiver of customary closing conditions. BTIG and Needham are acting as joint book running managers for the offering.
Fly Intel: After-Hours Movers » 17:5004/1304/13/22
VLNS, AGX, AIRG, ANSS, DLO, DOW, CMBM, RENT, PTGX, OCX, ES
Check out this evening's…